Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

@article{Aft2010EffectOZ,
  title={Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.},
  author={Rebecca L. Aft and Michael C Naughton and Kathryn Trinkaus and Mark Watson and Lourdes R Ylagan and Mariana Chavez-MacGregor and Jing Zhai and Sacha T Kuo and William Shannon and Kathryn Diemer and Virginia Herrmann and Jill R. Dietz and Amjad Ali and Matthew Ellis and Peter J Weiss and Timothy J. Eberlein and Cynthia Ma and Paula M. Fracasso and Imran Zoberi and Marie Taylor and William Gillanders and Timothy J. Pluard and Joanne Mortimer and Katherine N. Weilbaecher},
  journal={The Lancet. Oncology},
  year={2010},
  volume={11 5},
  pages={421-8}
}
BACKGROUND Treatment with bisphosphonates decreases bone loss and can increase disease-free survival in patients with breast cancer. The aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells (DTCs) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer. METHODS Patients were recruited for this open-label, phase 2 randomised trial between March 17, 2003, and May 19, 2006, at a single centre. Eligible patients had… CONTINUE READING